Drug Profile
Research programme: muscle activators - Cytokinetics
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Cytokinetics
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Muscle protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 26 Apr 2018 Cytokinetics intends to initiate phase I trials for a sarcomere directed compound in Quarter four of 2018
- 03 Jan 2018 Cytokinetics plans to advance a cardiac sarcomere directed compound from research into IND-enabling studies in 2018